Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics

NCT02189837 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02189837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02189837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Placebo-controlled, Single Site Study to Evaluate the Effects of Evolocumab (AMG 145) Treatment, Alone and in Combination With Atorvastatin, on Lipoprotein Kinetics
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
July 8, 2014
Completion date
March 5, 2015
Enrollment
89 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

primary hyperlipidemia and mixed dyslipidemia